FibroGen Inc (NASDAQ:FGEN) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $76.33.
Several research firms recently commented on FGEN. Zacks Investment Research lowered FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. TheStreet lowered FibroGen from a “c-” rating to a “d+” rating in a report on Wednesday, November 21st. BidaskClub lowered FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Leerink Swann set a $84.00 price objective on FibroGen and gave the company a “buy” rating in a report on Monday, October 15th. Finally, ValuEngine raised FibroGen from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th.
FibroGen stock traded down $2.96 during midday trading on Monday, hitting $37.97. 961,451 shares of the company were exchanged, compared to its average volume of 436,377. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -21.95 and a beta of 2.13. FibroGen has a fifty-two week low of $37.64 and a fifty-two week high of $68.55. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.20.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.15). The company had revenue of $29.00 million for the quarter, compared to analyst estimates of $36.48 million. FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. The firm’s revenue for the quarter was down 28.6% compared to the same quarter last year. Equities analysts expect that FibroGen will post -1.55 EPS for the current year.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction that occurred on Wednesday, November 21st. The stock was sold at an average price of $39.37, for a total value of $1,560,469.32. Following the sale, the chief executive officer now directly owns 2,676,088 shares of the company’s stock, valued at $105,357,584.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Roberto Pedro Rosenkranz sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $56.95, for a total value of $56,950.00. Following the completion of the sale, the director now directly owns 33,700 shares in the company, valued at $1,919,215. The disclosure for this sale can be found here. Over the last three months, insiders sold 229,773 shares of company stock worth $11,424,203. 8.96% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its stake in shares of FibroGen by 6.9% in the third quarter. FMR LLC now owns 8,981,236 shares of the biopharmaceutical company’s stock worth $545,610,000 after acquiring an additional 576,417 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of FibroGen by 1.8% in the third quarter. Vanguard Group Inc. now owns 6,921,874 shares of the biopharmaceutical company’s stock worth $420,503,000 after acquiring an additional 125,186 shares during the last quarter. BlackRock Inc. boosted its stake in shares of FibroGen by 1.9% in the third quarter. BlackRock Inc. now owns 6,301,117 shares of the biopharmaceutical company’s stock worth $382,796,000 after acquiring an additional 118,460 shares during the last quarter. Hillhouse Capital Management Ltd. boosted its stake in shares of FibroGen by 3.2% in the second quarter. Hillhouse Capital Management Ltd. now owns 2,686,196 shares of the biopharmaceutical company’s stock worth $168,156,000 after acquiring an additional 83,850 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of FibroGen by 37.8% in the third quarter. First Trust Advisors LP now owns 1,652,213 shares of the biopharmaceutical company’s stock worth $100,372,000 after acquiring an additional 453,288 shares during the last quarter. 64.86% of the stock is currently owned by institutional investors.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.